Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080605 | 0.89 | BTK (0.43) | BTKHDAC6EPHB4CFDHDAC1 | |
| SCHEMBL4080189 | 0.89 | BTK (0.44) | BTKHDAC6CFD | |
| SCHEMBL4095342 | 0.86 | BTK (0.39) | BTKHDAC6EPHB4 | |
| SCHEMBL13765445 | 0.83 | BTK (0.47) | BTKHDAC6HDAC1 | |
| SCHEMBL3000846 | 0.82 | BTK (0.70) | BTKHDAC6 | |
| SCHEMBL13771351 | 0.82 | BTK (0.56) | BTKHDAC6HDAC1 | |
| SCHEMBL4096542 | 0.81 | BTK (0.55) | BTKHDAC6 | |
| SCHEMBL4093084 | 0.80 | SYK (0.42) | BTKHDAC1 | |
| SCHEMBL13771751 | 0.78 | BTK (0.47) | BTKHDAC6EPHB4 | |
| SCHEMBL2996265 | 0.78 | TGFBR1 (0.40) | BTKHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885HDAC6 1266/4885EPHB4 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.